Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1990 1
1991 4
1993 2
1994 1
1996 3
1997 1
1998 1
1999 2
2000 2
2001 3
2002 5
2003 7
2004 6
2005 7
2006 7
2007 4
2008 11
2009 12
2010 15
2011 15
2012 8
2013 22
2014 19
2015 19
2016 28
2017 20
2018 15
2019 21
2020 18
2021 38
2022 38
2023 40
2024 36
2025 48
2026 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

438 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean biologic infection risk self (5,028 results)?
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. Ann Rheum Dis. 2024. PMID: 37827694 Free article.
Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative measures for infections, osteoporosis, cardiovascular disease. CONCLUS …
Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antipho …
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. Furie R, et al. Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
In post hoc sensitivity analyses evaluating higher SELENA-SLEDAI score thresholds, 10 mg/kg belimumab achieved better discrimination at weeks 52 and 76. Risk of severe flares over 76 weeks (based on the modified SLE Flare Index) was reduced with 1 mg/kg belimumab (3 …
In post hoc sensitivity analyses evaluating higher SELENA-SLEDAI score thresholds, 10 mg/kg belimumab achieved better discrimination at week …
Belimumab for systemic lupus erythematosus.
Singh JA, Shah NP, Mudano AS. Singh JA, et al. Cochrane Database Syst Rev. 2021 Feb 25;2(2):CD010668. doi: 10.1002/14651858.CD010668.pub2. Cochrane Database Syst Rev. 2021. PMID: 33631841 Free PMC article.
BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. ...SELECTION CRITERIA: We included randomized contro …
BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to …
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, Fanouriakis A. Kostopoulou M, et al. Ann Rheum Dis. 2024 Oct 21;83(11):1489-1501. doi: 10.1136/ard-2023-225319. Ann Rheum Dis. 2024. PMID: 38777375 Free PMC article.
The research questions focused on five different domains, namely the benefit/harm of SLE treatments, the benefits from the attainment of remission/low disease activity, the risk/benefit from treatment tapering/withdrawal, the management of SLE with antiphosph …
The research questions focused on five different domains, namely the benefit/harm of SLE treatments, the benefits from the attainment …
Perioperative management of disease-modifying antirheumatic drugs and other immunomodulators.
Moreira PM, Correia AM, Cerqueira M, Gil MF. Moreira PM, et al. ARP Rheumatol. 2022 Oct 1;1(ARP Rheumatology, nº3 2022):218-224. ARP Rheumatol. 2022. PMID: 36057090 Free article. Review. English.
In the case of Systemic Lupus Erythematosus (SLE), one should consider the severity of the condition to make the decision about discontinuing immunomodulators (mycophenolate mofetil, azathioprine, cyclosporine, or tacrolimus) as these should be continued in severe SLE …
In the case of Systemic Lupus Erythematosus (SLE), one should consider the severity of the condition to make the decision about disco …
Effect of Inflammation and Infection on Lipids and Lipoproteins.
Feingold KR, Grunfeld C. Feingold KR, et al. 2025 Jun 18. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2025 Jun 18. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 26561701 Free Books & Documents. Review.
Chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriasis and infections, such as periodontal disease and HIV, are associated with an increased risk of cardiovascular disease. Patients with these disor …
Chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriasis and infections …
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.
Donskey CJ, Dubberke ER, Klein NP, Liles EG, Szymkowiak K, Wilcox MH, Lawrence J, Bouguermouh S, Zhang H, Koury K, Bailey R, Smith HM, Lockhart S, Lamberth E, Kalina WV, Pride MW, Webber C, Anderson AS, Jansen KU, Gruber WC, Kitchin N. Donskey CJ, et al. Clin Infect Dis. 2024 Dec 17;79(6):1503-1511. doi: 10.1093/cid/ciae410. Clin Infect Dis. 2024. PMID: 39180325 Free PMC article. Clinical Trial.
BACKGROUND: Clostridioides difficile infection (CDI) causes substantial mortality and healthcare burden. We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention. METHODS: This phase 3 observer-blinded study randomized (1:1) 50-year-olds at incr …
BACKGROUND: Clostridioides difficile infection (CDI) causes substantial mortality and healthcare burden. We assessed the detoxified t …
EBV and Autoimmunity.
Cortese M, Ascherio A, Bjornevik K. Cortese M, et al. Curr Top Microbiol Immunol. 2025 Jul 4. doi: 10.1007/82_2025_304. Online ahead of print. Curr Top Microbiol Immunol. 2025. PMID: 40608093
Although the role of Epstein-Barr virus (EBV) in autoimmunity is biologically plausible and evidence of altered immune responses to EBV is abundant in several autoimmune diseases, inference on causality requires the determination that disease risk is higher in indiv …
Although the role of Epstein-Barr virus (EBV) in autoimmunity is biologically plausible and evidence of altered immune responses to E …
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
Rodziewicz M, Dyball S, Lunt M, McDonald S, Sutton E, Parker B, Bruce IN; British Isles Lupus Assessment Group Biologics Register (BILAG-BR) consortium. Rodziewicz M, et al. Lancet Rheumatol. 2023 May;5(5):e284-e292. doi: 10.1016/S2665-9913(23)00091-7. Lancet Rheumatol. 2023. PMID: 38251591 Free article.
BACKGROUND: Patients with systemic lupus erythematosus (SLE) are at an increased risk of infection relative to the general population. We aimed to describe the frequency and risk factors for serious infections in patients with moderate-to …
BACKGROUND: Patients with systemic lupus erythematosus (SLE) are at an increased risk of infection relative to the gene …
EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.
van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, Combe B, Cope AP, Deane KD, England BR, Falahee M, de Jong PHP, Kleyer A, Lacaille D, Maat B, Mankia K, van Mulligen E, Nagy G, O'Neil LJ, Rodamaker L, Sahbudin I, van Schaardenburg D, Sepriano A, da Silva JAP, De Smet L, Sparks JA, Steyerberg EW, Studenic P, Wethington E, Landewé RL, Raza K, van der Helm-van Mil AHM. van Steenbergen HW, et al. Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8. Ann Rheum Dis. 2025. PMID: 40447498 Free article.
OBJECTIVES: The field of rheumatoid arthritis (RA) is moving towards identification of and intervention in people at risk of RA, but a validated risk stratification method is lacking. This work was undertaken to develop a risk stratification method for person …
OBJECTIVES: The field of rheumatoid arthritis (RA) is moving towards identification of and intervention in people at risk of RA, but …
438 results